Search Results

• • 14 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy

  Authors:Guru Sonpavde, Gregory R. Pond, William R. Berry, Ronald de Wit, Mario A. Eisenberger, Ian F. Tannock, et al.From:Cancer (Vol. 117, Issue 17) Peer-Reviewed

  Sept. 1, 2011 Report

   Citation Only

• Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT(super3) antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials

  Authors:Richard J. Gralla, Ronald de Wit, Jorn Herrstedt, Alexandra D. Carides, Juliana Ianus, Julie Guoguang-Ma, et al.From:Cancer (Vol. 104, Issue 4) Peer-Reviewed

  Aug. 15, 2005 Article

   Citation Only

• Docetaxel in hormone-refractory metastatic prostate cancer: a viewpoint by Ronald de Wit

  Author:Ronald de WitFrom:Drugs (Vol. 65, Issue 16) Peer-Reviewed

  Nov. 1, 2005571 words Article 1460LProstate cancer is the most common cancer among men and is the second leading cause of cancer death in males. For decades, chemotherapy in patients who had become androgen independent (hormone-refractory prostate...

• Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials

  Authors:Michael T. Schweizer, Peng Huang, Michael W. Kattan, Adam S. Kibel, Ronald de Wit, Cora N. Sternberg, et al.From:Cancer (Vol. 119, Issue 20) Peer-Reviewed

  Oct. 15, 2013 Report

   Citation Only

• Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

  Authors:Ronald de Wit, Johann de Bono, Cora N. Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wulfing, et al.From:The New England Journal of Medicine (Vol. 381, Issue 26) Peer-Reviewed

  Dec. 26, 201951 words Report

   Citation Only

• Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study

  Authors:Saroj Niraula, Greg Pond, Ronald de Wit, Mario Eisenberger, Ian F. Tannock, and Anthony M. JoshuaFrom:Canadian Urological Association Journal (Vol. 7, Issue 1-2) Peer-Reviewed

  Feb. 1, 20132,974 words Report 1560LAuthor(s): Saroj Niraula, MD, Greg Pond, PhD, PStat, Ronald de Wit, MD, PhD, Mario Eisenberger, MD, Ian F. Tannock, MD, PhD, Anthony M. Joshua, BSc(Med) MBBS PhD FRACP Introduction Patients with advanced cancer...

• Overview of bladder cancer trials in the European Organization for Research and Treatment

  Author:Ronald de WitFrom:Cancer (Vol. 97, Issue 8) Peer-Reviewed

  Apr. 15, 2003 Article

   Citation Only

• Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor-support

  Authors:Ronald de Wit, Jaap Verweij, Marijke Bontenbal, Wim H.J. Kruit, Caroline Seynaeve, Paul I.M. Schmitz, et al.From:Journal of the National Cancer Institute (Vol. 88, Issue 19) Peer-Reviewed

  Oct. 2, 1996439 words Article

   Abstract Only

• First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma

  Authors:Anneke M. Westermann, Ellen L. Jones, Baard-Christian Schem, Elzbieta M. van der Steen-Banasik, Peter Koper, Olav Mella, et al.From:Cancer (Vol. 104, Issue 4) Peer-Reviewed

  Aug. 15, 2005 Article

   Citation Only

• Increased survival with enzalutamide in prostate cancer after chemotherapy

  Authors:Howard I. Scher, Kurt Miller, Andrew J. Armstrong, Mark Fleming, Lynn Seely, Karim Fizazi, et al.From:The New England Journal of Medicine (Vol. 367, Issue 13) Peer-Reviewed

  Sept. 27, 201277 words Clinical report

   Citation Only

• Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

  Authors:Daniel P Petrylak, Ronald de Wit, Kim N Chi, Alexandra Drakaki, Cora N Sternberg, Hiroyuki Nishiyama, et al.From:The Lancet (Vol. 390, Issue 10109) Peer-Reviewed

  Nov. 18, 20171,304 words Article

   Abstract Only

• Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma

  Authors:Ronald De Wit, Charles A.B. Boucher, Kees H.N. Veenhof, Jan K.M.E. Schattenkerk, Piet J.M. Bakker, and Sven A. DannerFrom:The Lancet (Vol. 2, Issue 8622) Peer-Reviewed

  Nov. 26, 1988 Article

   Citation Only

• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

  Authors:Ian F. Tannock, Ronald de Wit, William R. Berry, Jozsef Horti, Anna Pluzanska, Kim N. Chi, et al.From:The New England Journal of Medicine (Vol. 351, Issue 15) Peer-Reviewed

  Oct. 7, 200442 words Article

   Citation Only

• Impact of the Treating Institution on Survival of Patients With "Poor-Prognosis" Metastatic Nonseminoma

  Authors:Laurence Collette, Richard J. Sylvester, Sally P. Stenning, Sophie D. Fossa, Graham M. Mead, Ronald de Wit, et al.From:Journal of the National Cancer Institute (Vol. 91, Issue 10) Peer-Reviewed

  May 19, 1999311 words Article

   Abstract Only